CSL (OTCMKTS:CSLLY) Rating Lowered to “Strong Sell” at Zacks Research

CSL (OTCMKTS:CSLLY) was downgraded by Zacks Research from a “hold” rating to a “strong sell” rating in a note issued to investors on Monday,Zacks.com reports.

Several other research firms have also commented on CSLLY. Royal Bank Of Canada lowered CSL from a “moderate buy” rating to a “hold” rating in a report on Wednesday, February 11th. Citigroup lowered CSL from a “strong-buy” rating to a “hold” rating in a report on Monday. One analyst has rated the stock with a Strong Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the company has a consensus rating of “Hold”.

CSL Price Performance

Shares of CSL stock opened at $17.75 on Monday. The company has a debt-to-equity ratio of 0.51, a current ratio of 2.57 and a quick ratio of 1.15. CSL has a fifty-two week low of $17.64 and a fifty-two week high of $44.86. The business has a 50-day moving average price of $24.02 and a 200 day moving average price of $46.65.

About CSL

CSL Limited (OTCMKTS: CSLLY) is a global biotechnology company headquartered in Melbourne, Australia that develops, manufactures and delivers a range of plasma-derived and recombinant therapeutics, vaccines and related services. Its principal businesses include CSL Behring, which focuses on specialty biotherapies for bleeding disorders, immune deficiencies, hereditary angioedema and other serious conditions; Seqirus, an influenza vaccine company formed following CSL’s acquisition of Novartis’ influenza vaccine business; and CSL Plasma, a network of plasma collection centers that supplies the raw material for many of its therapies.

The company’s product portfolio spans immunoglobulins, clotting factor concentrates, albumin and other protein-based treatments used in the management of chronic and acute rare diseases, as well as seasonal and pandemic influenza vaccines.